IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Arovella Therapeutics Limited
Arovella Therapeutics is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry. In 2025 the company generated total revenue of $3,830,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Arovella Therapeutics is Unknown Michael James Baker whose official title is CHIEF EXECUTIVE OFFICER. The Chairman of Arovella Therapeutics is Dr Elizabeth Stoner whose official title is Interim Non-Executive Chairman. Arovella TherapeuticsLimted is a pharmaceutical developer focusing on the oncology and central nervous system (CNS) areas. The company is based in Melbourne Victoria, however opperates internationally with patents and contracts with counties such as Japan and the USA. Arovella currently has the following treatment and products under its brand: iNKT Cell Therapy Platform - Supplied by the Imperial College London and used in the treatment of blood cancers DKK1-Car-iNKT CAR19-iNKT + CF33-CD19 Anagrelide - Used in the reduction of platelets and lowering of thrombotic risk in myeloproliferative diseases associated with high platelet counts. ZolpiMist - An oral based spray containing zolpidem tartrate used in aiding sleep quality.
Access this data your way
The Arovella Therapeutics Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Arovella Therapeutics Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
Arovella Therapeutics Limited, trading as Arovella Therapeutics, operates under the ABN 35 090 987 250 and was incorporated on 21 December 1999. Arovella Therapeutics Limited trades on the Australian Securities Exchange under the ticker code ASX:ALA. Arovella Therapeutics Limited primarily operates in the Pharmaceutical Product Manufacturing industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within Arovella Therapeutics Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents Arovella Therapeutics Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Arovella Therapeutics Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of Arovella Therapeutics Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of Arovella Therapeutics Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Arovella Therapeutics Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of Arovella Therapeutics Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is Arovella Therapeutics Limited?
Arovella TherapeuticsLimted is a pharmaceutical developer focusing on the oncology and central nervous system (CNS) areas. The company is based in Melbourne Victoria, however opperates internationally with patents and contracts with counties such as Japan and the USA. Arovella currently has the following treatment and products under its brand: iNKT Cell Therapy Platform - Supplied by the Imperial College London and used in the treatment of blood cancers DKK1-Car-iNKT CAR19-iNKT + CF33-CD19 Anagrelide - Used in the reduction of platelets and lowering of thrombotic risk in myeloproliferative diseases associated with high platelet counts. ZolpiMist - An oral based spray containing zolpidem tartrate used in aiding sleep quality.
What industry does Arovella Therapeutics Limited operate in?
Arovella Therapeutics Limited, trading as Arovella Therapeutics, is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry in Australia.
Where is Arovella Therapeutics Limited located?
Murray Cod Australia Limited company is based at 62 Lygon Street, Carlton, Victoria, Australia.
Who is the CEO of Arovella Therapeutics Limited?
The DIRECTOR of Arovella Therapeutics Limited is Michael James Baker and the DIRECTOR is Michael Baker.
What was Arovella Therapeutics Limited’s revenue in 2025?
In 2025, Arovella Therapeutics Limited generated total revenue of approximately $3.8 million.
Cut through the noise with intelligence you can trust
